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Abstract 
 
Problem: The prevalence of regulatory T cells (Tregs) is lower in preeclampsia (PE) 
compared to healthy pregnancy (HP). However, the proportion of recently described Treg 
subtypes has not been investigated. 
Method: Peripheral blood samples of 19 PE and 21 HP women in the third trimester were 
evaluated using flow cytometry for the prevalence of activated T cells and naive, effector, 
thymic, extrathymic, and exhausted Tregs. 
Results: The prevalence of activated T cells and exhausted Tregs was higher in PE than in 
HP. The prevalence of the functionally most active effector Tregs is decreased, while naive 
Tregs appear to be unaffected in PE compared to HP. No difference was detected between 
Tregs according to their origin (thymic or extrathymic). 
Conclusion: The combination of lower effector Treg and higher exhausted Treg prevalence 
may account for the decrease in the functionality of Tregs in PE. 
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Introduction 
 
Preeclampsia (PE) is an immune-mediated syndrome usually developing in the third trimester 
of pregnancy characterized by an excessive maternal systemic inflammatory response with 
activation of both the innate and adaptive arms of the immune system.
1,2
 The maternal 
immune tolerance towards the developing semi-allogeneic fetus present in healthy pregnancy 
(HP) is compromised in PE. Activated neutrophils, monocytes, and natural killer cells initiate 
inflammation, which induces endothelial dysfunction, and activated T cells may support 
inadequate maternal tolerance mechanisms. An important feature of systemic inflammation in 
PE is the absence of Th2 skewness characteristic for HP, and thus the predominance of a Th1-
type immunity.
3
 
Regulatory T cells (Tregs) are mediators of the maternal immune tolerance towards the 
developing fetus. The FoxP3 transcription factor has been widely used as an intracellular 
marker to identify this subset. Tregs modulate the functions of other T cells (both CD4+ and 
CD8+), primarily through secretion of cytokines, including IL-10 and TGF-β.4,5 Evidence for 
the role of Treg cells in establishing fetal tolerance during pregnancy comes from animal 
studies, demonstrating a significantly increased rate of fetal resorption in allogeneic gestations 
of Treg-deficient mice.
6-8
 Lower than normal Treg frequency may contribute to the 
exaggerated systemic inflammation also in humans in PE. Indeed, a number of groups 
including ours demonstrated that the prevalence of peripheral Tregs is lower in PE compared 
to healthy pregnancy.
9-13 
While these studies mainly investigated peripheral blood, the 
distribution of Tregs in the decidua might differ. Earlier investigations provided evidence for 
the selective migration of fetus-specific Tregs from peripheral blood to the decidua, further 
emphasizing the importance of studying Tregs at the fetomaternal interface.
14-15 
Another 
study, evaluating both peripheral blood and decidual Treg cells in mostly severe PE patients 
confirmed that the proportion of Tregs was decreased in both locations compared to normal 
term controls.
16
 
Based on different intra- and extracellular markers, recent investigations identified that Tregs 
are not a homogenous cell subset, but can divided into further subgroups. Tregs have been 
grouped according whether they originate from the thymus (naturally occurring or nTregs) or 
induced in the periphery (iTregs). The Helios transcription factor, belonging to the Ikaros 
family, has been identified as a marker of thymic-derived Treg cells.
17
 Its function is not yet 
fully understood. Binding to the promoter region of FoxP3, it may have a role in regulating 
the expression of FoxP3.
18
 It does not seem to have a direct effect on Treg prevalence or 
function.
19
 Both nTregs and iTregs have a high expression of CD25 and CTLA-4, and low 
expression of CD127. These two subsets are different in the cytokines they produce and their 
potential to suppress other cells: iTregs produce IL-10 and IL-17 and have a higher regulatory 
potential. 
Miyara et al. categorized Tregs based on their expression of CD45RA and FoxP3. CD4+ 
FoxP3+ CD45RA+ cells were described as naive or resting Tregs, while CD4+ FoxP3hi 
CD45RA- cells were regarded as fully functional effector Tregs. CD4+ FoxP3+ CD45RA- 
cells are cytokine-secreting, non-suppressive T cells.
20
 CD45RA was also used by other 
groups as a marker of distinction.
21,22 
While naive Tregs have the potential to proliferate, 
effector Tregs are not capable of proliferation or further differentiation.
23
 
An “exhausted” and dysfunctional phenotype of Tregs has been reported in conditions of 
chronic disease and infection.
24
 Exhausted Tregs express CD279 or programmed death 
receptor 1 (PD-1), a negative regulatory molecule. Lines of evidence indicate that CD279 
expression on T cells is associated with limited proliferative capacity and reduced immune 
suppression in vivo.
25-29
 Interestingly, one of the ligands for CD279, CD274 (PD-L1), has 
been shown to negatively regulate Tregs by inhibiting STAT-5 phosphorylation at sites of 
chronic inflammation. Thus PD-1 and its ligand appear to be a major inhibitory receptor 
pathway involved in T cell exhaustion.
26
 
In this study, we aimed to compare the peripheral prevalence of activated T cells and Treg 
subtypes, such as naive and effector, thymic and extrathymic, as well as exhausted Tregs in 
PE and HP. 
 
Methods 
 
Sample collection 
We enrolled 19 women with PE at on average the 34th gestational week of pregnancy. PE was 
diagnosed according to standard internationally accepted criteria. These include hypertension 
(defined as systolic blood pressure and/or diastolic blood pressure ≥ 140 mmHg and ≥ 90 
mmHg, respectively) occurring after 20 weeks of gestation, and proteinuria (defined as 
presence of ≥ 0.3 g protein in a 24 hour urine specimen). As controls, 21 healthy, age-
matched pregnant women at on average the 36th gestational week were enrolled. Clinical 
characteristics of participants are summarized in Table I. PE was regarded as severe if any of 
the following criteria was present: blood pressure ≥ 160 mmHg systolic or ≥ 110 mmHg 
diastolic, or proteinuria ≥ 5 g/24 h (or 3+ on dipstick). Early onset of PE was defined as onset 
of the disease before 34 weeks of gestation. Informed consent was obtained from all subjects, 
and our study was reviewed and approved by an independent ethical committee of the 
institution (Scientific and Research Ethics Committee, Semmelweis University, Budapest, 
Hungary). The study was adhered to the tenets of the most recent revision of the Declaration 
of Helsinki. 
 
Flow cytometry 
Peripheral blood mononuclear cells (PBMCs) were separated by a standard density gradient 
centrifugation (Ficoll Paque, Amersham Biosciences AB, Uppsala, Sweden, 25 minutes, 400 
g, 22 °C) from freshly drawn blood collected in lithium heparin-treated tubes (BD Vacutainer, 
BD Biosciences, San Jose, CA, USA). Cells were kept at -80 °C in Fetal Bovine Serum 
containing 10% DMSO until analysis. After thawing, cells were washed twice in phosphate 
buffered saline. 
PBMCs were stained for 30 min at room temperature in the dark with PE Cy7-conjugated 
CD4, APC-conjugated CD25, APC-Cy7-conjugated CD279 and FITC-conjugated CD45RA 
(BioLegend, San Diego, CA, USA). After washing, cells were fixed with 
Fixation/Permeabilization solution and treated with Permeabilization Buffer according to the 
manufacturer’s instructions (eBioscience, San Diego, CA, USA).  They were then stained 
with PE-conjugated FoxP3 PE, and PerCP-conjugated Helios for 30 min at 4 °C in the dark. 
Mouse IgG1 antibodies were used as isotype control. 
After washing, cells were analyzed on a BD FACSAria flow cytometer (BD Biosciences). 
Data were processed using the FACSDiVa software. 200 000 cells per sample were recorded. 
 
Statistics 
Data are expressed as median and interquartile range (IQR). Comparisons between two 
sample populations were made with the Mann-Whitney U test, as a test of normality 
(according to Kolmogorov-Smirnoff) indicated non-normal distribution of data; p-values less 
than 0.05 were considered significant. Statistics were calculated using the GraphPad software 
(Prism version 5.00 for Windows, GraphPad Software, San Diego, CA, USA). 
 
Results 
 
Our results are summarized in Figure 1 and Table II. Within CD4+ T cells, the prevalence of 
CD4+ CD25hi FoxP3+ regulatory T cells was lower in women with PE than in HP women 
(4.63 (4.22-5.56) % vs. 3.69 (3.32-4.09) %, p = 0.0003). 
In PE, the prevalence of CD45RA- effector regulatory T cells among CD4+ cells was also 
decreased (2.44 (1.02-6.78) % vs. 0.87 (0.45-1.22) %, p = 0.0098), while that of CD45RA+ 
naive regulatory T cells did not differ between the two groups. However, when investigating 
the prevalence of naive Tregs within the Treg subset, an increase in PE was detected (57.3 
(30.9-77.8) % vs. 75.2 (46.0-87.9) %, p = 0.0014).  
The percentage of activated CD4+ T cells was higher in women with PE than in the control 
group (2.56 (0.55-7.02) % vs. 4.30 (1.78-7.85) %, p = 0.0456). 
Within the regulatory T cells, the prevalence of CD279+ exhausted Tregs was higher in 
women with PE than in HP women (8.08 (4.16-13.5) % vs. 18.2 (9.27-36.3) %, p = 0.0223). 
The prevalence of other regulatory T cell subtypes (Helios+ effector Tregs, Helios+ naive 
Tregs, thymic Tregs, extrathymic Tregs) did not differ between the two groups. 
 
Discussion 
 
In this study, we analyzed the prevalence of recently described regulatory T cell subsets in PE 
compared to HP. As many studies have noted before,
9-13
 the percentage of Tregs, identified as 
CD4+ CD25hi FoxP3+ cells, was lower in PE than in HP, contributing to the compromised 
maternal immune tolerance towards the semi-allogeneic fetus characteristic for PE, and to the 
loss of control over activated T cells. Indeed, the proportion of CD4+ CD25+ FoxP3+ 
CD45RA- activated T cells was higher among CD4+ T cells in PE compared to HP. This 
might in turn contribute to the increased Th1 type response and imbalance of Th1/Th2 ratio.
3
 
Nevertheless, our results indicate that the decrease in the prevalence of Treg cells is specific 
for certain Treg subtypes, while other subsets of these regulatory cells remain unaffected in 
PE. Interestingly, of all investigated subsets, the prevalence of the functionally most active 
effector Tregs (CD4+ FoxP3++ CD45RA-) is decreased to the highest extent, while naive 
Treg cells appear to be unaffected. A further factor that may contribute to the decreased 
functionality of Tregs in PE is that the prevalence of exhausted, functionally less active Tregs 
(CD4+ CD25hi FoxP3+ CD279+) is higher compared to HP. In line with these findings in 
pregnancy, an exhausted and dysfunctional phenotype of Tregs has been reported before in 
chronic disease and infection.
24
 The combination of lower effector Treg and higher exhausted 
Treg prevalence may account not only for the lower Treg proportion, but also for the observed 
decrease in the functionality of Tregs in PE.
30
 
The Helios transcription factor belongs to the Ikaros family and is expressed by thymic-
derived Treg cells.
17
 Samstein et al. reported that extrathymic generation of regulatory T cells 
enforces maternal-fetal tolerance in placental mammals.
7
 In addition, Hsu et al. demonstrated 
that the expansion of CD4+ Helios- Foxp3+ iTreg cells, rather than CD4+ Helios+ Foxp3+ 
nTreg cells, accounts for Treg expansion in HP. This expansion was found to be even more 
pronounced in the decidua, where an overrepresentation of iTreg cells was found. In PE, 
however, impaired systemic iTreg cell expansion was described, associated with a lack of 
iTreg cell overrepresentation in the decidua.
31 
On the other hand, Inada et al. recently 
observed that Helios+ effector nTreg cells are decreased in the decidua of miscarriage cases 
with normal fetal chromosomal content, and their data suggest that these cells might play an 
important role in the maintenance of pregnancy in humans.
32
 According to our results, the 
origin of Tregs in the periphery does not seem to play an important role in their activity in PE, 
since no alteration was detected in the proportion of thymic and extrathymic Tregs (CD4+ 
CD25hi FoxP3+ Helios+ and CD4+ CD25hi FoxP3+ Helios-, respectively) between the two 
study groups. Furthermore, Helios+ effector and naive Tregs are also of comparable 
prevalence in HP and PE. 
Earlier studies demonstrated that the prevalence of Tregs is decreased not only on the 
systemic level in peripheral blood of PE patients, but also locally, within the decidual 
tissue.
14,16
 A limitation of our study is that our findings represent circumstances in peripheral 
blood only. Therefore, further studies on the expression of the investigated Treg cell subtypes 
in the decidua are required to identify their role played in mediating tolerance at the 
fetomaternal interface. Moreover, the functional activity of Treg cell subsets should also be 
examined in healthy pregnancy and preeclampsia in future studies. 
 
Conclusion 
 
In summary, the decrease in the prevalence of Treg cells in PE is specific for certain Treg 
subtypes. No difference was detected between Tregs according to their origin (thymic or 
extrathymic). The prevalence of the functionally most active effector Tregs is decreased to the 
highest extent, while naive Treg cells appear to be unaffected. The combination of lower 
effector Treg and higher exhausted Treg prevalence may account for the decrease in the 
functionality of Tregs in PE. 
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Table I. Clinical characteristics of study participants 
 Healthy pregnant women 
(n = 21) 
Preeclamptic women 
(n = 19) 
Age (years) 32 (28-33) 33 (28-34) 
Systolic blood pressure (mmHg) 115 (100-125) 160* (140-180) 
Diastolic blood pressure (mmHg) 70 (55-80) 95* (85-120) 
Gestational age at blood sample 
collection (week) 
36 (35-37) 34 (31-37) 
Gestational age at birth (week) 39 (37-41) 35* (31-38) 
Fetal birth weight (g) 3340 (2870-3650) 2770* (2100-3450) 
Early onset preeclampsia - 5 (26%) 
Severe preeclampsia - 7 (37%) 
 
Data are presented as median (interquartile range) for continuous variables and as number 
(percentage) for categorical variables. * p < 0.05 versus healthy pregnant women 
 
Table II. Prevalence of the investigated cell subsets 
 
Subset Marker HP (n = 21) PE (n = 19) p 
Treg CD4+ CD25hi FoxP3+/CD4+ 4.63 (4.22-5.56) % 3.69 (3.32-4.09) % 0.0003 
Effector Treg CD4+ FoxP3++ CD45RA-/CD4+ FoxP3+ 30.5 (17.7-40.2) % 17.1 (9.88-25.6) % 0.0022 
Naive Treg CD4+ FoxP3+ CD45RA+/CD4+ FoxP3+ 57.3 (30.9-77.8) % 75.2 (46.0-87.9) % 0.0014 
Effector Treg CD4+ FoxP3++ CD45RA-/CD4+ 2.44 (1.02-6.78) % 0.87 (0.45-1.22) % 0.0098 
Naive Treg CD4+ FoxP3+ CD45RA+/CD4+ 4.58 (2.35-7.89) % 3.76 (2.11-5.67) % 0.1098 
Activated T CD4+ CD25+ FoxP3+ CD45RA-/CD4+ 2.56 (0.55-7.02) % 4.30 (1.78-7.85) % 0.0456 
Helios+ Effector CD4+ FoxP3++ CD45RA- Helios+/CD4+ FoxP3++ CD45RA- 72.0 (49.1-96.8) % 73.1 (50.2-92.3) % 0.9159 
Helios+ Naive CD4+ FoxP3+ CD45RA+ Helios+/CD4+ FoxP3+ CD45RA+ 56.9 (40.5-67.7) % 63.0 (37.2-75.3) % 0.8973 
Thymic Treg CD4+ CD25hi FoxP3+ Helios+/CD4+ CD25hi FoxP3+ 60.5 (39.9-87.2) % 60.2 (28.7-90.0) % 0.7053 
Extrathymic Treg CD4+ CD25hi FoxP3+ Helios-/CD4+ CD25hi FoxP3+ 39.5 (12.8-60.1) % 39.8 (10.1-71.8) % 0.6202 
Exhausted Treg CD4+ CD25hi FoxP3+ CD279+/CD4+ CD25hi FoxP3+ 8.08 (4.16-13.5) % 18.2 (9.27-36.3) % 0.0223 
 
Data are presented as median (interquartile range). HP – healthy pregnancy, PE – preeclampsia 
Figure legend 
 
Figure 1. Box-plots representing the frequency of the investigated cell subsets in healthy 
pregnancy (HP) and preeclampsia (PE). Horizontal line: median; Box: interquartile range (25-
75 percentile); Whisker: range. * p < 0.05 versus HP 
 
